HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer-Reference-Cited by-同舟云学术

HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer

Published:2021-08-18 Issue:1 Volume:190 Page:155-163
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

de Moura Leite Luciana^ORCID,Cesca Marcelle Goldner^ORCID,Tavares Monique Celeste^ORCID,Santana Debora Maciel,Saldanha Erick Figueiredo^ORCID,Guimarães Paula Tavares,Sá Daniella Dias Silva^ORCID,Simões Maria Fernanda Evangelista^ORCID,Viana Rafael Lima^ORCID,Rocha Francisca Giselle,Loose Simone Klog,Silva Sinara Figueiredo,Pirolli Rafaela^ORCID,Fogassa Camilla Albina Zanco^ORCID,Mattos Bruna Raphaeli Silva,Campos Fernando Augusto Batista^ORCID,Sanches Solange Moraes^ORCID,de Lima Vladmir Cláudio Cordeiro^ORCID,Pondé Noam Falbel^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-021-06365-7.pdf

Reference29 articles.

1. Goutsouliak K, Veeraraghavan J, Sethunath V et al (2020) Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol 17:233–250. https://doi.org/10.1038/s41571-019-0299-9

2. Cesca MG, Vian L, Cristóvão-Ferreira S et al (2020) HER2-positive advanced breast cancer treatment in 2020. Cancer Treat Rev 88:102033. https://doi.org/10.1016/j.ctrv.2020.102033

3. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. https://doi.org/10.1126/science.3798106

4. Cameron D, Piccart-Gebhart MJ, Gelber RD et al (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389:1195–1205. https://doi.org/10.1016/S0140-6736(16)32616-2

5. Delaloge S, Antoine A, Debled M et al (2020) 279MO Divergent evolution of overall survival across metastatic breast cancer (MBC) subtypes in the nationwide ESME real life cohort 2008–2016. Ann Oncol 31:S352–S353. https://doi.org/10.1016/j.annonc.2020.08.381

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Landscape of HER2-low breast cancer: Insights from a six-year study on prevalence and clinicopathological characteristics;Annals of Diagnostic Pathology;2024-10

2. Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterations;World Journal of Surgical Oncology;2024-09-12

3. Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy;Scientific Reports;2024-07-23

4. The Prognostic Impact of HER2-Low and Menopausal Status in Triple-Negative Breast Cancer;Cancers;2024-07-17

5. HER2-Low Breast Cancer: Now and in the Future;Cancer Research and Treatment;2024-07-15